Progyny (NASDAQ:PGNY) Stock Price Target Raised at Leerink Partners

Progyny (NASDAQ:PGNY) had its price objective lifted by Leerink Partners from $37.00 to $38.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners‘s price objective suggests a potential upside of 10.69% from the company’s previous close.

PGNY has been the topic of a number of other research reports. Barclays decreased their price target on Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 12th. Wall Street Zen downgraded shares of Progyny from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 31st. BTIG Research increased their price objective on shares of Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Citigroup reissued a “market outperform” rating on shares of Progyny in a report on Thursday. Finally, KeyCorp boosted their target price on shares of Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Eleven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.92.

Progyny Stock Performance

PGNY traded up $4.23 during trading hours on Thursday, reaching $34.33. The company’s stock had a trading volume of 1,824,614 shares, compared to its average volume of 1,360,782. Progyny has a 52 week low of $16.10 and a 52 week high of $35.50. The company’s 50-day moving average is $27.11 and its 200-day moving average is $24.49. The firm has a market cap of $2.63 billion, a PE ratio of 37.31, a price-to-earnings-growth ratio of 2.01 and a beta of 0.97.

Progyny (NASDAQ:PGNY) last posted its earnings results on Wednesday, November 4th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.31 by $0.21. The company had revenue of $341.25 million for the quarter, compared to the consensus estimate of $340.76 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.15 earnings per share. Equities analysts anticipate that Progyny will post 1.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Melissa B. Cummings sold 1,879 shares of Progyny stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total value of $52,612.00. Following the completion of the transaction, the chief operating officer directly owned 66,496 shares of the company’s stock, valued at approximately $1,861,888. This trade represents a 2.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin K. Gordon sold 11,500 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $27.94, for a total transaction of $321,310.00. Following the transaction, the director directly owned 6,792 shares in the company, valued at approximately $189,768.48. This represents a 62.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 17,282 shares of company stock valued at $475,790. 9.90% of the stock is currently owned by company insiders.

Institutional Trading of Progyny

A number of hedge funds have recently bought and sold shares of the business. Public Employees Retirement System of Ohio bought a new stake in shares of Progyny in the 2nd quarter worth approximately $29,000. Nykredit A S bought a new position in Progyny in the 2nd quarter valued at $38,000. IFP Advisors Inc increased its stake in Progyny by 376.0% in the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after acquiring an additional 1,549 shares during the last quarter. Toth Financial Advisory Corp purchased a new stake in Progyny in the second quarter valued at approximately $65,000. Finally, Integrated Wealth Concepts LLC bought a new stake in shares of Progyny during the 2nd quarter worth $74,000. 94.93% of the stock is currently owned by institutional investors.

Progyny News Roundup

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Quarterly results topped expectations: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million. Revenue rose 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Progyny Q3 results
• Positive Sentiment: Higher earnings outlook: The company raised its 2026 earnings guidance and provided a fourth-quarter outlook, a key catalyst behind the more favorable analyst commentary. Progyny raises 2026 earnings guidance
• Positive Sentiment: Analysts raised price targets: Citizens JMP lifted its target to $38 and maintained a “market outperform” rating; Cantor Fitzgerald raised its target to $35 and kept an “overweight” rating. Both cited the improved outlook. Citizens JMP target increase
• Positive Sentiment: Growth indicators: A Q3 analysis highlighted new client wins and margin expansion, supporting the case for continued business momentum. Q3 analysis

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.